Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › mycosis fungoides

Mycosis fungoides

Part of Non-Hodgkin's Lymphoma

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for mycosis fungoides

11 trials tracked for mycosis fungoides: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 587 citations.

11Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 7 Phase 1 2 Other / NA 1
  1. Phase 3 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Completed · 587 cited
  2. Phase 2 Mechlorethamine Induced Contact Dermatitis Avoidance Study Completed
  3. Phase 2 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas Completed
  4. Phase 2 Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome Completed
  5. Phase 2 Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Completed
  6. Phase 2 Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL Completed
Show 5 more trials
  1. Phase 2 Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides Completed
  2. Phase 2 Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides Completed
  3. Phase 1 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies Completed
  4. Phase 1 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Completed
  5. N/A Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Mycosis fungoides: what the trials found

Brentuximab Vedotin has demonstrated clinical efficacy in patients with mycosis fungoides. In a Phase 3 trial, Brentuximab Vedotin resulted in a complete response (CR) rate of 17.2% (p=0.0002) 1. Additionally, this intervention showed significant improvement in patient-reported outcomes, specifically a maximum change from baseline in the symptom domain score of the Skindex-29 questionnaire (-28.08; -8.62, p=<0.001) 1.

Further evaluation of Brentuximab Vedotin in a Phase 2 trial confirmed its use in this patient population 5.

Recent results — preliminary, needs further review

  • Pembrolizumab showed a -5.015% change in mSWAT score in a Phase 2 study 2.
  • Triamcinolone was evaluated in a Phase 2 trial (not yet corroborated) 3.
  • Cyclosporine was assessed for achieving full myeloid and donor T-cell chimerism 4.
  • Rosiglitazone and Bexarotene were evaluated; however, zero participants achieved a 50% improvement in baseline skin score 6.
  • CPG 7909 was investigated in a Phase 2 trial 7.

For the clinician treating this condition

  • Brentuximab Vedotin is established as an effective intervention, achieving significant improvements in both complete response rates and Skindex-29 symptom scores [1, 5].
  • Clinical data for several other agents, including mechlorethamine-MCH and rhIL-15, are currently unconfirmed or from early-phase trials.

AI synthesis of 7 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mogamulizumab monotherapy achieves 41.2% overall response rate in patients with cutaneous T-cell lymphomas
Dermatology Meta-analysis
Mogamulizumab monotherapy achieves 41.2% overall response rate in patients with cutaneous T-cell lymphomas Mogamulizumab Shows Meaningful Response in Cutaneous T-cell Lymphoma
This systematic review and meta-analysis of 453 patients evaluated mogamulizumab for Cutaneous T-cell Lymphomas, including Mycosis Fungoides…
New data shows mogamulizumab may be more effective for patients with Sézary Syndrome and blood involvement in certain skin cancers.
Jul 2, 2026
CXCL13 quantification in PBMCs and plasma distinguishes Sézary syndrome from other cutaneous T-cell lymphomas and dermatoses
Allergy & Immunology Cohort
CXCL13 quantification in PBMCs and plasma distinguishes Sézary syndrome from other cutaneous T-cell lymphomas and dermatoses A simple blood test could spot a rare skin cancer faster
This cohort study analyzed CXCL13 expression in peripheral blood mononuclear cells (PBMCs) and plasma concentrations in patients with suspec…
A simple blood test for a protein called CXCL13 may help doctors catch a rare, aggressive skin cancer that often looks like eczema for years…
Frontiers Apr 13, 2026